MARKET

PAVM

PAVM

PAVmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.50
0.00
0.00%
Opening 12:59 06/22 EDT
OPEN
6.48
PREV CLOSE
6.50
HIGH
6.70
LOW
6.36
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
6.70
52 WEEK LOW
1.630
MARKET CAP
545.15M
P/E (TTM)
-12.1337
1D
5D
1M
3M
1Y
5Y
Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology industry leader Tim Baxter, to its Board of D...
GlobeNewswire · 06/14 13:30
Medrio Selected as Exclusive Data Management Solution for Leading Device and Diagnostic Sponsor
/PRNewswire-PRWeb/ -- Medrio, Inc., a leading provider of decentralized and eClinical technology to pharmaceutical, biotech, medical device, diagnostics, and animal health markets, has been selected as the exclusive data management vendor for PAVmed Inc. (...
PR Newswire - PRF · 06/14 13:00
Here's Why We're Not Too Worried About PAVmed's (NASDAQ:PAVM) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, PAVmed...
Simply Wall St. · 06/14 09:06
PAVmed Gets CE Mark Certification for Esophageal Cancer Test
marketwatch.com · 06/10 14:00
PAVmed Reports Its Lucid Diagnostics Completes European CE Mark Certification Of Its EsoGuard Esophageal DNA Test
PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc.
Benzinga · 06/10 13:31
BRIEF-Pavmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification Of Its Esoguard Esophageal Dna Test
reuters.com · 06/10 13:31
PAVmed forms digital health company, Veris Health
PAVmed ([[PAVM]] +2.1%) launched a new subsidiary, digital health company Veris Health, which acquired digital health company Oncodisc which has groundbreaking tools to improve personalized cancer care through remote patient monitoring."PAVmed is entering
Seekingalpha · 06/02 14:19
BRIEF-Pavmed Inc Launches Digital Health Company Veris Health Inc.
reuters.com · 06/02 13:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PAVM. Analyze the recent business situations of PAVmed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PAVM stock price target is 8.63 with a high estimate of 9.50 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 18.20M
% Owned: 21.71%
Shares Outstanding: 83.87M
TypeInstitutionsShares
Increased
36
5.60M
New
35
4.37M
Decreased
10
559.47K
Sold Out
9
209.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.88%
Healthcare Equipment & Supplies
+0.62%
Key Executives
Chairman/Chief Executive Officer/Director
Lishan Aklog
President/Chief Financial Officer/Secretary
Dennis McGrath
President/Chief Financial Officer/Secretary
Dennis Mcgrath
Vice Chairman/Independent Director
Michael Glennon
Other
Brian DeGuzman
Director
Tim Baxter
Director
Debra White
Independent Director
James Cox
Independent Director
Ronald Sparks
Independent Director
David Weild
No Data
About PAVM
PAVmed Inc. is a medical device company organized to conceive, develop and commercialize a diversified pipeline of products. The Company's products include PortIO, Caldus, CarpX, NextCath, DisappEAR and NextFlo. PortIO is an implantable vascular access device, which does not require accessing the central venous system and does not have an indwelling intravascular component. CarpX is a percutaneous device to treat carpal tunnel syndrome. NextCath is a self-anchoring catheter, which does not require suturing, traditional anchoring techniques or add-on catheter securement devices. The Company's DisappEAR is an Antibiotic-eluting Resorbable Ear Tubes. The Company is engaged in developing and commercializing antibiotic-eluting resorbable ear tubes based on an aqueous silk technology conceived and developed at these institutions. The Company is engaged in developing disposable infusion system with variable flow resistors. Caldus is a disposable tissue ablation device.

Webull offers kinds of PAVmed Inc stock information, including NASDAQ:PAVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PAVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PAVM stock methods without spending real money on the virtual paper trading platform.